Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.

Journal Article

We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.

Full Text

Duke Authors

Cited Authors

  • Franzetti, M; Pozzetti, U; Carugati, M; Pandolfo, A; Molteni, C; Faccioli, P; Castaldo, G; Longoni, E; Ormas, V; Iemoli, E; Piconi, S

Published Date

  • August 2020

Published In

Volume / Issue

  • 97 /

Start / End Page

  • 215 - 218

PubMed ID

  • 32422376

Pubmed Central ID

  • 32422376

Electronic International Standard Serial Number (EISSN)

  • 1878-3511

Digital Object Identifier (DOI)

  • 10.1016/j.ijid.2020.05.050


  • eng

Conference Location

  • Canada